Stock INZY INOZYME PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-15 pm EDT 		5-day change 1st Jan Change
5.46 USD +6.02% Intraday chart for Inozyme Pharma, Inc. +18.70% +28.17%
Jul. 02 Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency MT
Jul. 02 Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency DJ

Evolution of the average Target Price on Inozyme Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

40a15814.Z2p-6sZSb_nCzHYpQic2ieSirKD0z51W2L0ULNaYYfc.IgUHm58iAY6JgE5jFkpj2bLv9dOdv94zqf94T-DoVK0rBwi_gx8czICDHQ~42465fa16b7e30003a69b7689ddeb73f

Analyst Recommendations on Inozyme Pharma, Inc.

Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target MT
Jefferies Upgrades Inozyme Pharma to Buy From Hold, Adjusts Price Target to $6 From $4.50 MT
Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating MT
Wedbush Adjusts Inozyme Pharma Price Target to $20 From $23, Maintains Outperform Rating MT
Jefferies & Co. Initiates Inozyme Pharma, Inc at Hold, Price Target Set at $5 MT
HC Wainwright Lowers Inozyme Pharma's Price Target to $20 From $33, Maintains Buy Rating MT
Wedbush Adjusts Price Target for Inozyme Pharma to $23 From $25, Maintains Outperform Rating MT
Wedbush Adjusts Inozyme Pharma's Price Target to $25 From $35, Citing Cost of Capital; Outperform Rating Kept MT
HC Wainwright Starts Inozyme Pharma at Buy With $33 Price Target MT
Needham Starts Inozyme Pharma at Buy With $23 Price Target MT
Wedbush Trims Inozyme Pharma's Price Target to $35 From $37; Outperform Rating Kept MT
INOZYME PHARMA : Wedbush Adjusts Price Target on Inozyme Pharma to $37 From $35, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.46 USD
Average target price
20 USD
Spread / Average Target
+266.30%
High Price Target
40 USD
Spread / Highest target
+632.60%
Low Price Target
14 USD
Spread / Lowest Target
+156.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Inozyme Pharma, Inc.

Wells Fargo Securities
Jefferies & Co.
Wedbush
HC Wainwright
Needham & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INZY Stock
  4. Consensus Inozyme Pharma, Inc.